Date: November 2, 2022
Time: 7:00am (PDT), 10:00pm (EDT), 4:00pm (CEST)
As part of the immune response, inflammation plays a vital role in the host defense and is dictated by the balance between stimulatory and inhibitory mediators. Inappropriate regulation of inflammation is an underlying contributor to many common pathological conditions. RNA and protein biomarkers can be effective indicators of (patho-)physiological processes and therefore their accurate quantitation critical to better understand the causative mechanisms of various (inflammatory) disorders. High-throughput multiplex protein and gene expression assays are valuable tools allowing for efficient detection of multiple analytes of interest to further drive biomarker discovery and verification across various research fields. This presentation will provide an understanding of unique Luminex xMAP-based multiplex assay solutions (RUO) that enable comprehensive detection of both RNA and protein targets in parallel on the same instrument platform. With the new Immune Response panel the largest multiplex protein assay is now available on the Luminex xMAP-based system that enables researchers to measure 80 key soluble factors simultaneously, providing a more holistic picture of the immune response network. To accelerate your research even further the 384-well assay format allows to increase sample throughput while maintaining the assay performance as compared to the 96-well format.
- Discover the new multiplex assay portfolio for high-throughput immune response profiling
- Highlight the differences between the 96-well and 384-well formats and compare performance data of high-plex panels
- Outline immune monitoring approaches to characterize immune response profiles
Webinars will be available for unlimited on-demand viewing after live event.
Labroots is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E. ® Program. By attending this webinar, you can earn 1 Continuing Education credit once you have viewed the webinar in its entirety.